Category Specific RSS

myelofibrosis

Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%

Heads have turned in biotech circles with an ASX filing confirming that Platinum Asset Management has increased its stake in…

2 years ago

Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib

Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer…

2 years ago

Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials

Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis…

2 years ago

Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions

In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the…

2 years ago

Pharmaxis progresses FDA discussions, set to expand bone marrow cancer trial to treat more patients

A large cohort of patients around the world diagnosed with myelofibrosis (aka bone marrow cancer) will soon be able to…

3 years ago

German researchers publish ‘best ever’ results for urgently needed blood cancer treatment

There is an urgent need for better treatment for myelodysplastic syndrome (MDS), a type of blood cancer, and new research…

3 years ago